image: A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. view more
Credit: K Pinker, et al., Medical University of Vienna, Vienna, Austria
Reston, VA--Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy, according to new research published in the January issue of The Journal of Nuclear Medicine. By comparing healthy contralateral breast tissue of patients with malignant breast tumors and benign breast tumors, researchers found that multiple differences in biomarkers can be assessed with PET/MRI imaging, which could impact risk-adapted screening and risk-reduction strategies in clinical practice.
In breast cancer, early detection remains key to improved prognosis and survival. While screening mammography has decreased mortality for breast cancer patients by 30 percent, its sensitivity is limited and is decreased in women with dense breast tissue. "Such shortcomings warrant further refinements in breast cancer screening modalities and the identification of imaging biomarkers to guide follow-up care for breast cancer patients," said Doris Leithner, MD, research fellow at Memorial Sloan Kettering Cancer Center in New York, New York. "Our study aimed to assess the differences in 18F-FDG PET/MRI biomarkers in healthy contralateral breast tissue among patients with malignant or benign breast tumors."
The study included 141 patients with imaging abnormalities on mammography or sonography on a tumor-free contralateral breast. The patients underwent combined PET/MRI of the breast with dynamic contrast-enhanced MRI, diffusion-weighted imaging (DWI) and the radiotracer 18F-FDG. In all patients, several imaging biomarkers were recorded in the tumor-free breast: background parenchymal enhancement and fibroglandular tissue (from MRI), mean apparent diffusion coefficient (from DWI) and breast parenchymal uptake (from 18F-FDG PET). Differences among the biomarkers were analyzed by two independent readers.
A total of 100 malignant and 41 benign lesions were assessed. In the contralateral breast tissue, background parenchymal enhancement and breast parenchymal uptake were decreased and differed significantly between patients with benign and malignant lesions. The difference in fibroglandular tissue approached but did not reach significance, and the mean apparent diffusion coefficient did not differ between the groups.
"Based on these results, tracer uptake of normal breast parenchyma in 18F-FDG PET might serve as another important, easily quantifiable imaging biomarker in breast cancer, similar to breast density in mammography and background parenchymal enhancement in MRI," Leithner explained. "As hybrid PET/MRI scanners are increasingly being used in clinical practice, they can simultaneously assess and monitor multiple imaging biomarkers--including breast parenchymal uptake--which could consequently contribute to risk-adapted screening and guide risk-reduction strategies."
###
The authors of "Multiparametric 18F-FDG PET-MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?" include Doris Leithner, Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA, University Hospital Frankfurt, Department of Diagnostic and Interventional Radiology, Frankfurt, Germany, and Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria; Thomas H. Helbich, Panagiotis Kapetas and Pascal A. T. Baltzer, Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria; Blanca Bernard-Davila, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Maria Adele Marino, Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA, and Department of Biomedical Sciences and Morphologic and Functional Imaging, University of Messina, Messina, Italy; Daly Avendano, Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA, and Department of Breast Imaging, Breast Cancer Center TecSalud, ITESM Monterrey, Nuevo Leon, Mexico; Danny F. Martinez, Maxine S. Jochelson and Elizabeth A. Morris, Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Alexander Haug, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria, and Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, Vienna, Austria; Marcus Hacker, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria; Yasemin Tanyildizi, Department of Neuroradiology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and Katja Pinker, Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA, and Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.
This study was made available online in June 2019 ahead of final publication in print in January 2020.
Please visit the SNMMI Media Center for more information about molecular imaging and precision medicine. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About The Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit http://www.snmmi.org.
Journal
Journal of Nuclear Medicine